AuraGenix BioPharma Expands Marketing Strategies for 2009; Exhibits at IMCAS 2009 in Paris and Anti-Aging Medicine World Congress in Monaco

Share Article

AuraGenix BioPharma, a wholly owned subsidiary of AuraGenix N.V. reported today that the Company will increase its marketing budgets in 2009 by as much as 300% over Fiscal 2008. The Company is attending IMCAS 2009 in Paris, January 8th -11th and will exhibit at The Anti-Aging Medicine World Congress in Monaco, March 22nd-24th.

Auragenix Biopharma Ltd. (, a wholly owned subsidiary of Auragenix N.V. reported today that the Company will increase its marketing budgets in 2009 by as much as 300% over Fiscal 2008. The Company says that it has agreed to participate in two major industry Conferences and Trade Exhibits in the first half of calendar 2009, including the IMCAS 2009 Annual Meeting in Paris, France, Jan 8th-11th and The Anti-Aging Medicine World Congress- Monaco, March 22nd-24th.

Says Khasha Ighanian, Senior Vice-President, Marketing, "Our business today defines one of the fastest growing and most dynamic segments of the 'Quality of Life' medical services sector. This sector is currently enjoying significant innovation that has profound impact on the range and types of medical treatment available today and tomorrow for anti-aging and image enhancement." Explains Mr. Ighanian, "AuraGenix BioPharma will play a major role in the months and years ahead in providing the aesthetics marketplace with new and highly effective solutions in both injectible medical devices and topical therapies. We anticipate that our presence at both IMCAS 2009 this week and The anti-Aging Medicine World Conference in Monaco will serve to strengthen and expand our competitive market position, as well as create greater awareness among both the professional and patient population for the high quality, high performance products we offer."

AuraGenix Biopharma will showcase at IMCAS 2009 it's Revanesse® family of hyaluronic acid based derma fillers, which are rapidly earning a leadership position in the anti-aging and facial aesthetic marketplace worldwide. The Revanesse® line of HA derma fillers(Revanesse, Revanesse Ultra, and ReDexis) made its debut in 2006 and is currently sold in more than 30 countries worldwide. Revanesse® is used by dermatologists, medical practitioners and clinicians as a long lasting derma filler that will erase fine lines and wrinkles, smooth deep folds and give lips a natural, fuller look.

Established in 2008 and headquartered in Malta, AuraGenix BioPharma Ltd. ( is the exclusive global distributor for anti-aging and aesthetic products designed, developed and manufactured by its Affiliate, Prollenium Medical Technologies, Aurora, Ontario, Canada

Shares of AuraGenix N.V., the parent company of AuraGenix BioPharma, are listed on the Open Market segment of the Frankfurt Exchange. A public offering of AuraGenix shares was not made in connection with their inclusion on the Open Market Frankfurt.

**AuraGenix BioPharma and Prollenium Medical Technologies are co-sharing Booths E-24-E26 at IMCAS 2009, PALAIS DES CONGRES DE PARIS, Jan 8th-11th.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

AuraGenix N.V.
Email >
Visit website